Observational Study on the Weight Effect of Insulin Detemir (Levemir®) in Type 2 Diabetics

Novo Nordisk A/S206 enrolled

Overview

This study is conducted in Europe. Observational study evaluating the body weight progress during the treatment with insulin detemir (Levemir®) in Type 2 patients, previously treated with other basal insulins

Study Type

OBSERVATIONAL

Enrollment

206

Conditions

Diabetes Diabetes Mellitus, Type 2

Interventions

insulin detemirDRUG

Start dose, frequency of dosing, dose titration to be prescribed by the physician as a result of a normal clinical evaluation

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Type 2 diabetes * Current treatment with insulin NPH or glargine * The selection of the subjects will be at the discretion of the individual physician Exclusion Criteria: * Current treatment with insulin detemir * Previous enrolment in this study * Hypersensitivity to insulin detemir or to any of the excipients. * Women who are pregnant, breast feeding or have the intention of becoming pregnant within next 12 months

Locations (1)

Novo Nordisk Investigational Site

Prague, Czechia

Outcomes

Primary Outcomes

Weight effect

Time frame: 12 months prior to and 12 months after detemir treatment.

Secondary Outcomes

Improvement in FPG levels

Time frame: 12 months prior and 12 months after detemir treatment

Improvement in HbA1c levels

Time frame: 12 months prior and 12 months after detemir treatment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.